Navigation Links
AXL1717 Clinical Data From Ongoing Phase I/II Study in Cancer Patients Will be Released in Connection With the ASCO Meeting in Chicago, June 2010
Date:5/17/2010

STOCKHOLM, May 17, 2010 /PRNewswire/ -- Axelar AB, a Karolinska Development portfolio company, today announces that a submitted abstract has been accepted to the ASCO meeting in Chicago, June 2010.

The abstract containing preliminary clinical data will be publicly released on ASCO's website, http://www.asco.org on Thursday, May 20, 2010 at 6:00 PM (EDT).

"We are pleased that the abstract containing a preliminary update of the favorable clinical data has been accepted by 2010 Annual Meeting of the American Society of Clinical Oncology", says Johan Harmenberg, CEO Axelar AB.

About Axelar

Axelar is a Swedish biotech company founded in 2003. The company is developing an insulin-like growth factor-1 (IGF-1) receptor inhibitor for cancer treatment. Axelar is part of the Karolinska Development portfolio. http://www.axelar.se

About AXL1717

Axelar's lead compound, AXL1717, provides a novel treatment for a wide range of cancers. AXL1717 is the first targeted oral small-molecule IGF-1 receptor inhibitor with no effect on the insulin receptor. AXL1717 is presently undergoing Phase I/II clinical trials and the compound combines a superior preclinical efficacy against numerous tumors with an excellent tolerability profile. Most tumor cells are dependent on the IGF-1 receptor signal pathway and the IGF-1 receptor is therefore regarded as an excellent target for cancer therapy. To date, there are no IGF-1 receptor inhibitor drugs on the market.

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation Pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio contains a total of 21 potential first-in-class products. http://www.karolinskadevelopment.com

For further information, please contact:

Johan Harmenberg, CEO, Axelar AB

Phone: +46-(0)705-14-54-53, e-mail: johan.harmenberg@axelar.se


'/>"/>
SOURCE Karolinska Development AB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
2. Novavax Announces Publication of a Pre-clinical Study with its Pandemic 2009 H1N1 Influenza Virus-Like Particle (VLP) Vaccine
3. Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial
4. Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial
5. Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C
6. Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
7. Anavex reports animal study results as lead Alzheimers compound approaches phase 1 clinical trials
8. Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program
9. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
10. Thursday News Highlights from the American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting and Clinical Congress
11. Mettler Toledo and PDS Pathology Data Systems Integrate Powerful Solutions for Faster and More Accurate Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
Breaking Biology News(10 mins):